Association of Lipidomics Signatures in Blood with Clinical Progression in Preclinical and Prodromal Alzheimer’s Disease
Fatemah Sakr, for the Alzheimer’s Disease Neuroimaging Initiative, Martin Dyrba, Anja Bräuer, Stefan Teipel
Abstract
BACKGROUND: Lipidomics may provide insight into biochemical processes driving Alzheimer's disease (AD) pathogenesis and ensuing clinical trajectories. OBJECTIVE: To identify a peripheral lipidomics signature associated with AD pathology and investigate its potential to predict clinical progression. METHODS: We used Bayesian elastic net regression to select plasma lipid classes associated with the CSF pTau/Aβ42 ratio as a biomarker of AD pathology in preclinical and prodromal AD cases from the ADNI cohort. Consensus clustering of the selected lipid classes was used to identify lipidomic endophenotypes and study their association with clinical progression. RESULTS: In the APOE4-adjusted model, ether-glycerophospholipids, lyso-glycerophospholipids, free-fatty acids, cholesterol esters, and complex sphingolipids were found to be associated with the CSF pTau/Aβ42 ratio. We found an optimal number of five lipidomic endophenotypes in the prodromal and preclinical cases, respectively. In the prodromal cases, these clusters differed with respect to the risk of clinical progression as measured by clinical dementia rating score conversion. CONCLUSION: Lipid alterations can be captured at the earliest phases of AD. A lipidomic signature in blood may provide a dynamic overview of an individual's metabolic status and may support identifying different risks of clinical progression.